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ABSTRACT 
There has been a widespread use of herbal medicines in the last two decades, despite a lack of scientific evidence for their efficacy and safety. Health 
care professionals have expressed growing concerns about safety issues relating to use herbal medicine, particularly in patients with renal or liver 
insufficiency. This review will propose how to use existing evidence to suggest the safe use of herbal medicines in patients with renal insufficiency, 
as well as transferring toxicity findings of herbal medicines from animal studies to use in humans.  
Safety information from postmarketing surveillance and case reports is likely to be the main information sources. However, there is little data 
relating to herbal medicines used by patients with chronic kidney disease. When human studies are lacking, animal studies can be seen as a 
substitute source of reliable information. An animal dose related to renal toxicity is used to calculate a theoretical human equivalent dose in order to 
estimate the toxicity in humans. However, this information should be used with caution. When herbal medicines used by people with renal 
insufficiency have, as yet, yielded no evidence of nephropathy, health care providers should regularly monitor kidney function of such people, 
together with their electrolytes. Observational studies are required to examine the renal adverse effects of herbal medicines. 
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INTRODUCTION 
The use of herbal medicine has been increasing worldwide over 
the last two decades, particularly by patients with chronic diseases 
and who are from Asian populations [1-3]. Prevalence of herbal 
use in patients with chronic kidney disease (CKD) ranges from 28-
57% [4-7]. Although research in this field has been increasing [8], 
there is a lack of studies about safety issues regarding herbal use. 
Findings from in vitro and in vivo are likely to be the main 
information sources of the efficacy and safety of herbal medicine 
due to limited clinical trials and few epidemiological studies. This 
may be because regulation of herbal medicines in many Asian and 
Western countries has classified these products as dietary 
supplements or traditional herbal medicines. As a result, their 
registration has not required information from clinical trials, 
compared with conventional medicine [9-12]. This paper will 
propose how to use existing evidence to suggest safe use of herbal 
medicines in patients with renal insufficiency, and transfer toxicity 
findings of herbal medicines from animal studies to use in humans. 
What available evidence is there for the safe use of herbal 
medicine? 
Due to a lack of clinical trials regarding information about the safety 
of herbal medicines (15% of published randomized controlled trials 
in herbal medicine, compared with conventional medicines)[13], a 
prospective cohort study seems to offer rigorous evidence, see fig. 1. 
However, there are a few cohort studies in patients with CKD. One 
such study reported that Chinese herbal medicines were associated 
with developing CKD, see table 1 [14]. A case-control study is further 
evidence for the need for concern over safety issues relating to 
herbal medicines. There are a small number of these studies. For 
instance, only three case-control studies of herbal medicines related 
to either developing CKD or end-stage renal disease [15-17]. 
Likewise, there are limited cross-sectional studies of renal adverse 
effects from using herbal medicines. Only three cross-sectional 
studies reported that herbal medicines were associated with 
developing CKD [18-20]. 
 
 
Fig. 1: Evidence hierarchy 
Adapted from Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: Is there a rigid hierarchy? Circulation 2008;118(16):1675-84. [21] RCTs = 
randomised controlled trials. 
Most of these observational studies did not specify a particular type 
of herbal medicine. They also reported herbal medicines as a whole, 
such as ‘Chinese herbal medicine’ or ‘traditional herbal medicine’. 
Additionally, the studies were only conducted in Taiwan and 
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Thailand. Therefore, safety information regarding the use of herbal 
medicines seems to be based on postmarketing surveillance or case 
reports. These reports have provided the information from several 
regions, such as Europe, the US and Africa (tables 1-2). 
Safety information from post-marketing surveillance and case 
reports 
Several countries  have established databases from their post-
marketing surveillance systems, such as the U. S. FDA Adverse Event 
Reporting System, Canada Vigilance Adverse Reaction Online 
Database, the Therapeutic Goods Administration (TGA) Database of 
Adverse Event Notifications in Australia, and the WHO International 
Drug Monitoring Programme. In addition, data from poison centers 
provide further evidence of herbal medicine being related to serious 
adverse events. For instance, the U.S. FDA Center for Food Safety and 
Nutrition reported that eight patients were admitted to hospital due to 
dietary supplement use. One death from stroke resulted from the use 
of dietary supplements that contained caffeine and yohimbe [26]. 
As known, a voluntary reporting system of adverse events is under-
reported [27], so there are only a limited number of reports on 
adverse effects, particularly herbal medicines as the culprit. From 
1971 to 2012, a database of adverse events in Australia reported 
only 0.67% of adverse events related to herbal medicines [28]. Thus, 
intensive surveillance of the products, particularly in Asian 
populations, is needed to build up information on the safety of 
product use. This information would support developing a guideline 
for the rational use of herbal medicine. 
A case report of herbal medicine related to adverse events is likely to 
be sufficient evidence to indicate whether or not people should 
avoid them. Forty-four case reports showed that herbal medicines or 
dietary supplements were associated with nephrotoxicity 
worldwide, see table 2 [29-32]. Existing literature reported that 
most herbal medicines were related to acute kidney injury [29].  
Meanwhile, there is a lack of evidence regarding herbal medicines 
associated with the progression of chronic kidney disease in patients 
with CKD. The severity of adverse events in case reports is classified 
into three levels [33]: a severe adverse event is defined as death; 
moderate and mild adverse events are defined as life-threatening 
and non-life-threatening adverse events, respectively. Herbal 
medicines related to either severe or moderate adverse events 
supported by a case report should be avoided.  
However, some herbal medicines, such as river spiderwort used by 
patients with CKD, have no reports on renal adverse effects [4]. 
Therefore, findings from animal studies are likely to be carefully 
evaluated in order to decide whether or not patients should avoid 
this medicine. 
 
Table 1: Examples of herbal medicines or dietary supplements related to severe adverse effects 
Information sources Herbal medicines or dietary 
supplements 
Adverse effects 
U. S. FDA Adverse Event Reporting System (FAERS) [22] Oxy Elite Pro® Liver failure 
Canada Vigilance Adverse Reaction Online Database 
[23] 
Propolis Acute renal failure 
Thaivigibase during 2007-2008 [24] Houttuynia cordata Acute renal failure 
Malaysia adverse drugs reaction advisory committee 
[25] 
Ya-Hom Powder Five Pagodas Brand Death 
A prospective cohort study in Taiwan [14] Chinese herbal medicines Developing CKD 
(OR 1.20, 95%CI 1.16-1.24) 
Three case-control study in Taiwan [15-17] Chinese herbal medicines or MuTong Developing CKD or end-stage renal 
disease 
A cross-sectional study in Taiwan [18] Chinese herbal medicines Developing CKD (adjusted OR 1.39, 
95%CI 1.20-1.70) 
A cross-sectional study in Thailand [20] Herbal medicines Developing CKD (adjusted OR 1.20, 
95%CI 1.02-1.42) 
OR = Odds ratio, CI = Confidence interval 
 
Table 2: Case reports on nephropathy related to herbal medicines or dietary supplements [29-32, 34] 
Country Herbal medicine Adverse effect 
Turkey Anatolian hawthorn (Crataegus orientalis) Acute interstitial nephritis 
Japan Bee pollen Acute interstitial nephritis 
South Africa Cape aloe (Aloe capensis) Acute tubular necrosis 
Peru Cat’s claw (Uncaria tomentosa) Acute interstitial nephritis 
US, Mexico Chaparral (Larrea tridentata) Renal cysts 
US CKLS (kidney, liver, spleen purifier contains Aloe vera, Cascara sagrada, Larrea tridentata, 
and Arctostaphyos uva-ursi) 
Acute interstitial nephritis 
 
Australia, US Cone flower (Echinacea) Acute kidney injury 
US Creatine Acute interstitial nephritis 
Malaysia Djenkol beans, jering (Pithecolobium lobatum) Acute tubular necrosis 
South Korea Gongjin-dan (Moschus moschiferus, Cervus elaphus, Angelica gigas, Cornus officinalis) Focal tubulointerstitial nephritis 
Italy, US Hemlock (Conium maculatum) Acute tubular necrosis 
Ireland Horse chestnut seed extract (Aesculus hippocastanum) Hemorrhage from renal 
amgiomyolipoma 
US, Germany Noni juice (Morinda citrifolia) Hyperkalemia 
Taiwan Pien Tze Huang (Panax notoginseng, snake’s gall bladder, dried cattle gall bladder stones, 
musk) 
Acute kidney injury 
Brazil, Taiwan Propolis Acute interstitial nephritis 
Hong Kong, 
Taiwan 
Star fruit (Averrhoa carambola) Oxalate nephropathy 
US, Europe Wormwood oil (Artemisia absinthium) Acute tubular necrosis 
US, West Africa Yohimbe (Pausinystalia yohimbe) Acute kidney injury 
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Table 3: Conversion of body surface area to body weight 
Species Body weight (kg) Km factor 
Human   
 Adult 60 37 
 Child 20 25 
Rabbit 1.8 12 
Guinea pig 0.4 8 
Rat 0.15 6 
Hamster 0.08 5 
Mouse 0.02 3 
Adapted from Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22(3):659-61. 
 
How to transfer toxicity informaion from animal studies to 
humans 
In the case of no reports on adverse effects of herbal medicines 
on humans, findings from animal studies seem to be crucial 
evidence to support a decision on herbal use in human beings. 
Several animal studies showed a toxic dose of herbal medicines 
leading to renal or liver toxicity.[35-37] This information is 
transferred to use in human by calculating a human equivalent 
dose from an animal dose.  
 
Table 4: Six classes of acute toxic effects 
Class Severity of toxicity A lethal dose in 50% of the population (LD50) 
1 Extreme toxicity <1 mg/kg 
2 High toxicity 1-50 mg/kg 
3 Moderate toxicity 50-500 mg/kg 
4 Low toxicity 500-5,000 mg/kg 
5 Practically non-toxic 5,000-15,000 mg/kg 
6 Relatively harmless >15,000 mg/kg 
 
Theoretical human equivalent dose (mg/kg) =  
Animal dose (mg/kg) × [ Animal Km
Human Km 
], see table 3 [38]. 
Severity of acute toxic effects from animal studies has been classified 
into 6 categories based on a lethal dose in 50% of the population 
(LD50
The following is an example of calculating a theoretical human 
equivalent dose from an animal dose: Yacon leaves for anti-diabetic 
agents in Brazil were experimented in rats. Nephrotoxicity was 
caused by 100 mg/kg of an aqueous extract from Yacon leaves [35]. 
1.8 grams of aqueous extract were prepared from 20 grams of dried 
leaves. From this information, the theoretical human equivalent dose 
of the Yacon extract was 16.2 mg/kg, which was equal to 180 mg of 
Yacon dried leaves per body weight (kg). It would appear that this 
dose is higher than a common dose of Yacon that people used for 
diabetes. LD
) determination in rats, see table 4 [33]. 
50
Recommendation for herbal use based on theoretical 
knowledge 
 of this herbal medicine is 5,000 mg/kg meaning low 
toxicity [39]. However, a Yacon water extract contains sesquiterpene 
lactones, which are likely to damage kidneys [35]. Therefore, Yacon 
should be used with caution, particularly by people with renal 
insufficiency. 
If there is no evidence of renal adverse effects in both human 
and animal studies, theoretical knowledge about adverse effects 
of herbal medicines is likely to be used, as a last resort, to 
provide guidance on the safe use of herbal medicines. For 
instance, the National Kidney Foundation and the National Lists 
of herbal medicinal products in Thailand  have recommended 
avoiding certain herbal medicines, such as senna, rhubarb, based 
on theoretical knowledge [40, 41]. The side effects of senna are 
water and electrolyte loss, which may cause dehydration when 
people use either a high dose or take it long term. Consequently, 
it may induce acute kidney injury, especially in patients with 
CKD. One case report showed that a woman aged 52 years took a 
high dose of senna for 3 years and had renal and liver failure 
[42]. 
Existing evidence showed inconsistency with rhubarb-induced 
kidney damage. Albersmeyer et al. (2012) reported that a patient 
with diabetes type 1 used 500 mg/day of rhubarb for a month 
and oxalate nephropathy was found [43]. Meanwhile, Khan et al. 
(2014) conducted randomized controlled trials in 160 patients 
with stages 3 and 4 CKD, who received rhubarb of 750 mg/day 
with conventional therapy for 3 months [44]. They found no 
difference in adverse effects between the treatment and control 
groups. The rhubarb group also showed the slower progression 
of CKD. Therefore, further studies are required in order to prove 
validate safety information based on theoretical knowledge. 
When the herbal medicines or dietary supplements used by patients 
with CKD have no any evidence on renal adverse effects, it is advisable as 
a precautionary measure that health care providers should regularly 
monitor such users’ kidney function and electrolytes. 
Summary 
Existing evidence on renal adverse events, which have been 
precipitated by the use of herbal medicines, is supported by post-
marketing surveillance and case reports. Due to a lack of information 
from human studies, animal studies seems to be a reliable source of 
information about renal and liver toxicity emanating from herbal 
medicines. Observational studies, such as case-control or cohort 
studies, are required to fill a gap in knowledge about the safety 
issues relating to herbal medicines. 
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